Harmony Biosciences Holdings, Inc. (HRMY) Stock Analysis & Investment Frameworks
Harmony Biosciences Holdings, Inc. (HRMY) stock analysis on Invetso. Review Harmony Biosciences Holdings, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Harmony Biosciences Holdings, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Harmony Biosciences Holdings, Inc. Key Financial Metrics
- Market Cap: $1.97B
- Revenue: $868.45M
- P/E Ratio: 12.47
- ROE: 18.55%
- ROIC: 15.41%
- Dividend Yield: N/A
About Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.